Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 34 (August 17 - August 21, 2026). The Program is carried out in accordance with Article 5 of R

Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, today announced the appointment of Chandra Ramanathan, Ph.D., M.B.A., as Executive Vice President of Commercializat

PALM SPRINGS, Calif., Aug. 24, 2026 /PRNewswire/ -- The VIVA Foundation will spotlight the latest advances in vascular medicine as 26 clinical trials are presented during The VEINS and VIVA 2026, taking place October 3-6 at Bellagio Las Vegas. The highly anticipated late-breaking presentations will provide attendees with early access to new evidence shaping the future of vascular care. For 24 years, VIVA (Vascular InterVentional Advances) has set the benchmark for premier education and cli

BEIJING, Aug. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026. InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company’s reven

SALT LAKE CITY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Unit (NAMRU) EURAFCENT, part of Navy Medicine Research & Development that is focused on infectious disease threats affecting military personnel, to evaluate SeekIt™, the company’s instrument-free molecular diagnostic platform. SeekI

ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- The Emmes Group today announced that its Board of Directors has appointed Dr. Rama Kondru as Chief Executive Officer, reflecting the company's commitment to advancing next-generation clinical trials that improve quality, speed, and patient outcomes. This appointment reflects the Board's confidence in Dr. Kondru's ability to drive innovation and operational excellence and underscores its commitment to advancing clinical research through scientific ex

First commercial deployment of FDB Script Agent™ with Tebra converts ambient encounter dialogue into structured prescriptions for clinician review, grounded in trusted medication intelligence SOUTH SAN FRANCISCO, Calif., Aug. 24, 2026 /PRNewswire/ -- FDB (First Databank, Inc.), the leading provider of clinically robust, AI-enabled medication intelligence that helps healthcare professionals make precise medication decisions and streamline medication workflows, today announced the first commercial

Unlike traditional models, the new division brings together transplant experts with a singular focus on organ transplantation, making it easier for physicians, scientists and educators across disciplines to collaborate AURORA, Colo. , Aug. 24, 2026 /PRNewswire/ -- Today, the University of Colorado Anschutz announced the creation of the Division of Transplant Medicine within the Department of Medicine, the first of its kind in the nation. The new division brings transplant specialists together in

Appointments add deep dermatology drug development and commercialization expertise as Amplifica advances its hair-growth pipeline SAN DIEGO, Aug. 24, 2026 /PRNewswire/ -- Amplifica Holdings Group, Inc. ("Amplifica"), a privately held, clinical-stage biopharmaceutical company developing novel therapies for hair growth, today announced the appointment of Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to its board of directors. The appointments strengthen Amplifica's leader

Company invites qualified clinicians to join the NVOX Network, its US clinical network, at no cost Multimodal platform is designed to reduce clinician workload and make comprehensive ADHD assessment easier to integrate into clinical practice NVOX Network launch follows more than three and a half years of development and more than 1,000 completed assessments during NVOX's initial operating phase NEWARK, Del., Aug. 24, 2026 /PRNewswire/ -- NVOX today announced the launch of the NVOX Network, its U